High Hopes and Altered Genes
Biotech has long been a high-risk, high-reward industry. It is an industry in which numerous firms, including many small-caps and start-ups, intensively research possible...
Boomers could see lower drug costs via imports
In an effort to ease prescription drug costs in the United States - especially for older Americans - four senators introduced legislation yesterday that will...
Research Total Return Leaders Based on compounded annual price appreciation and dividends for the 10-year period ending Nov. 13, 2008, for stocks trading at or above...
Stocks in health care, including biotech and pharmaceuticals, are poised for higher levels in 2008 - thanks to present valuations, developing pipelines and acquisition horizons,...
VC the Hard Way
"I spend 90 percent of my time on 5 percent of my clients' portfolios," says Dale Stevens, president of Grasswood Partners Inc., a Malibu, Calif....
A Time of Innovation
New products and other factors drive growth in health care/biotech, despite a cautious regulatory environment, analysts say. ----- Jason Kantor RBC Capital Markets 415-633-8565 Jason.email@example.com Outlook: Fundamentally, I don't think the...
Obesity: A Heavy Burden on Healthcare
Americans are growing larger and there seems to be no end in sight to this alarming trend.
A GOOD PROGNOSIS
HEALTH CARE FUNDS HAVEN'T BEEN WINNING ANY POPULARITY contests lately. Only $150 million flowed into the category in 2005, on the heels of a $1.45...
Buying The Future
If you were to suggest to colleagues or clients that the biotechnology sector presents a good opportunity for investment, they might very well respond with...
Evan McCulloch of Franklin Biotechnology Discovery Fund
S&P Rank: 3 Stars March 11, 2004 Biotechs High on Drug Approvals